GlassScriptPhysician profile
Thinh T Tang
NPI 1588042444
$10,333.95
in general payments reported to CMS, 2019-2025
34 companies · $1,744 in 2025
The $1,744 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,172 · 2020: $166 · 2021: $467 · 2022: $1,937 · 2023: $1,643 · 2024: $2,205 · 2025: $1,744.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,950 · Travel and Lodging: $591 · Education: $49.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,950.09 |
| Travel and Lodging | $591.38 |
| Education | $49.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,685.30 | 2019-2025 | Rinvoq, Skyrizi, Viberzi |
| Boston Scientific Corporation | $1,482.87 | 2019-2025 | Orcapod, Apollo Esg Nxt System |
| Janssen Biotech, INC. | $684.70 | 2022-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $603.72 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Medtronic, INC. | $591.38 | 2024 | Interstim |
| Genzyme Corporation | $459.40 | 2022-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $376.41 | 2019-2025 | Xifaxan, Plenvu |
| Gilead Sciences, INC. | $371.34 | 2019-2024 | Livdelzi |
| Celgene Corporation | $366.76 | 2022-2023 | Zeposia |
| Madrigal Pharmaceuticals | $289.74 | 2024-2025 | Rezdiffra, Resmetirom |
| Intercept Pharmaceuticals, INC. | $267.22 | 2019-2025 | Ocaliva |
| Nestle Healthcare Nutrition INC. | $249.53 | 2021-2023 | |
| Qol Medical, LLC | $198.78 | 2022-2025 | Sucraid, Sucraid |
| Cook Medical LLC | $190.45 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $178.69 | 2022-2025 | Dupixent |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $177.42 | 2022-2024 | Linzess |
| Lilly USA, LLC | $145.60 | 2023-2025 | Omvoh |
| Aimmune Therapeutics, INC. | $142.23 | 2024-2025 | Vowst |
| Daiichi Sankyo INC. | $125.21 | 2019 | |
| Exelixis INC. | $121.83 | 2019 | |
| Fujifilm Wako Diagnostics U.S.A. Corporation | $100.53 | 2019 | |
| Ardelyx, INC. | $92.19 | 2022-2025 | Ibsrela |
| Pfizer INC. | $63.01 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $55.58 | 2025 | Voquezna |
| Braintree Laboratories, INC. | $53.70 | 2022-2024 | Sutab, Suflave |
| Alnylam Pharmaceuticals INC. | $48.78 | 2022 | |
| Organon LLC | $45.81 | 2024 | |
| Merck Sharp & Dohme LLC | $36.68 | 2021-2024 | Winrevair |
| Redhill Biopharma INC. | $28.57 | 2022 | |
| Janssen Pharmaceuticals, INC | $25.87 | 2025 | Tremfya |
| Ipsen Biopharmaceuticals, INC | $23.02 | 2025 | Iqirvo |
| Lucid Diagnostics INC. | $22.67 | 2023 | |
| Eisai INC. | $14.83 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $14.13 | 2024 | Zeposia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thinh Tang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.